Inactivated UPEC-FimON

Phase 1

Inactivated UPEC-FimON is one of 11 therapeutic programs targeting Urinary Bladder Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Urinary Bladder NeoplasmsRecruiting

Urinary Bladder NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

11 competitors in Urinary Bladder Neoplasms

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

3 2

Lynparza

AstraZeneca

Phase 2

1 3

Padcev

Pfizer

Phase 1

2 4

Keytruda

Merck & Co.

Phase 1

1 5

Crestor

AstraZeneca

Phase 1

1 6

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 7

Lanoxin

AAdvanz Pharma

Phase 1

1 8

Trastuzumab Deruxtecan

AstraZeneca

Phase 1

1 9

Vepugratinib

Eli Lilly

Phase 2

3 10

Tuoyi

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Urinary Bladder Neoplasms

NCT07881666

Clinical

Trials by Indication[1]

Urinary Bladder Neoplasms1 trial

Phase I, Open-label, Multicenter Trial, to Evaluate the Safety and Tolerability of Intravesical Inactivated UPEC-FimON (Uro- Pathogenic E. Coli) in Participants With Non-Muscle Invasive Urothelial Carcinoma (NMIUC) of the Urinary Bladder, Who Failed Previous Bacillus Calmette-Guérin (BCG) or Intravesical Chemotherapy

Recruiting·HHopec Pharma·Phase 1·NCT07881666·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inactivated UPEC-FimON. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Inactivated UPEC-FimON. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hopec Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHopec Pharma

Inactivated UPEC-FimON

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Urinary Bladder Neoplasms1 trial

References

Drug Info

Quick Facts

Related News